학술논문
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Document Type
Article
Author
Lonial, S.; Nooka, A.K.; Lee, H.C.; Badros, A.; Trudel, S.; Chari, A.; Abdallah, A.-O.; Callander, N.; Lendvai, N.; Sborov, D.; Suvannasankha, A.; Weisel, K.; Karlin, L.; Libby, E.; Arnulf, B.; Facon, T.; Hulin, C.; Kortüm, K.M.; Rodríguez-Otero, P.; Usmani, S.Z.; Voorhees, P.M.; Hari, P.; Baz, R.; Quach, H.; Moreau, P.; Gupta, I.; Hoos, A.; Zhi, E.; Baron, J.; Piontek, T.; Dettman, E.J.; Opalinska, J.; Lewis, E.; Jewell, R.C.; Popat, R.; Esposti, S.D.; Richardson, P.; Cohen, A.D.
Source
In: The Lancet Oncology . (The Lancet Oncology, February 2020, 21(2):207-221)
Subject
Language
English
ISSN
14745488
14702045
14702045